Jazz Pharmaceuticals (JAZZ) EBIT Margin (2010 - 2026)

Jazz Pharmaceuticals' EBIT Margin history runs 17 years deep, the most recent figure standing at 31.49% for Q1 2026.

• In Q1 2026, EBIT Margin rose 3772.0% year-over-year to 31.49%; the TTM figure through Mar 2026 stood at 0.85% (down 1548.0% YoY), while the FY2025 annual figure was 10.08%, down 2769.0% from the prior year.
• EBIT Margin was 31.49% for Q1 2026 at Jazz Pharmaceuticals, up from 21.25% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 31.49% in Q1 2026 to a low of 65.64% in Q2 2025.
• Historically, EBIT Margin has averaged 6.52% across 5 years, with a median of 12.11% in 2023.
• The sharpest annual moves came in 2023 and 2025: EBIT Margin jumped 3920 bps in 2023, then sank 8512 bps in 2025.
• A 5-year view of EBIT Margin shows it stood at 27.09% in 2022, then surged by 145 bps to 12.11% in 2023, then surged by 45 bps to 17.53% in 2024, then increased by 21 bps to 21.25% in 2025, then surged by 48 bps to 31.49% in 2026.
• The last three EBIT Margin figures came in at 31.49% (Q1 2026), 21.25% (Q4 2025), and 5.11% (Q3 2025), per Business Quant data.